Sarepta Closes ENVISION Enrollment and Will Analyze Blinded Data

Sarepta said November 5 it will not reopen enrollment in Phase 3 ENVISION, which studied Elevidys in nonambulatory and late-ambulatory Duchenne muscular dystrophy and has been on global clinical hold since 2025. It will…




